NCT06442436View on ClinicalTrials.gov

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

December 12, 2025

Study Completion Date

December 12, 2025

Conditions
Hepatic Impairment (HI)
Interventions
DRUG

Nemtabrutinib

25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.

Trial Locations (3)

32809

RECRUITING

Orlando Clinical Research Center ( Site 0001), Orlando

33172

RECRUITING

Clinical Pharmacology of Miami ( Site 0003), Miami

78215

RECRUITING

Texas Liver Institute ( Site 0002), San Antonio

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY